Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 11/20 | 0.55 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | FPR1 | P21462 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25751207 | 0.88 | NLRP3 (0.53) | NLRP3PSMB1PSMB5ALDH1A1RXFP1 | |
| SCHEMBL25746482 | 0.88 | NLRP3 (0.53) | NLRP3PSMB1PSMB5ALDH1A1RXFP1 | |
| SCHEMBL24077223 | 0.88 | NLRP3 (0.53) | NLRP3 | |
| SCHEMBL30451187 | 0.85 | NLRP3 (0.55) | NLRP3PSMB1PSMB5CHRNA7KDM4E | |
| SCHEMBL24077225 | 0.85 | NLRP3 (0.55) | NLRP3PSMB1PSMB5CHRNA7KDM4E | |
| SCHEMBL24077283 | 0.85 | NLRP3 (0.55) | NLRP3PSMB1PSMB5CHRNA7KDM4E | |
| SCHEMBL26732432 | 0.85 | NLRP3 (0.55) | NLRP3PSMB1PSMB5CHRNA7KDM4E | |
| SCHEMBL30168561 | 0.84 | NLRP3 (0.49) | NLRP3FPR2 | |
| SCHEMBL25746474 | 0.84 | NLRP3 (0.49) | NLRP3FPR2 | |
| SCHEMBL26732250 | 0.83 | NLRP3 (0.59) | NLRP3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | NLRP3 1/4885PSMB1 1295/4885PSMB5 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.